{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:40:16Z","timestamp":1761237616191},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,3,20]],"date-time":"2009-03-20T00:00:00Z","timestamp":1237507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s00417-009-1066-x","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T07:25:57Z","timestamp":1237447557000},"page":"919-927","source":"Crossref","is-referenced-by-count":22,"title":["Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy"],"prefix":"10.1007","volume":"247","author":[{"given":"Qiong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingfa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shisheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Tong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,20]]},"reference":[{"key":"1066_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","volume":"26","author":"SX Zhang","year":"2007","unstructured":"Zhang SX, Ma JX (2007) Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 26:1\u201337, doi: 10.1016\/j.preteyeres.2006.09.002","journal-title":"Prog Retin Eye Res"},{"key":"1066_CR2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.exer.2006.01.016","volume":"83","author":"O Arjamaa","year":"2006","unstructured":"Arjamaa O, Nikinmaa M (2006) Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 83:473\u2013483, doi: 10.1016\/j.exer.2006.01.016","journal-title":"Exp Eye Res"},{"key":"1066_CR3","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/archopht.1995.01100120068012","volume":"113","author":"LP Aiello","year":"1995","unstructured":"Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA (1995) Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 113:1538\u20131544","journal-title":"Arch Ophthalmol"},{"key":"1066_CR4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0002-9394(01)01381-2","volume":"133","author":"MJ Tolentino","year":"2002","unstructured":"Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA (2002) Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133:373\u2013385. doi: 10.1016\/S0002-9394(01)01381-2","journal-title":"Am J Ophthalmol"},{"key":"1066_CR5","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","volume":"114","author":"MJ Tolentino","year":"1996","unstructured":"Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP (1996) Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114:964\u2013970","journal-title":"Arch Ophthalmol"},{"key":"1066_CR6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","volume":"114","author":"AP Adamis","year":"1996","unstructured":"Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D\u2019Amore PA, Miller JW (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114:66\u201371","journal-title":"Arch Ophthalmol"},{"key":"1066_CR7","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1073\/pnas.93.10.4851","volume":"93","author":"GS Robinson","year":"1996","unstructured":"Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE (1996) Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 93:4851\u20134856, doi: 10.1073\/pnas.93.10.4851","journal-title":"Proc Natl Acad Sci USA"},{"key":"1066_CR8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10456-007-9069-x","volume":"10","author":"J Bradley","year":"2007","unstructured":"Bradley J, Ju M, Robinson GS (2007) Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10:141\u2013148, doi: 10.1007\/s10456-007-9069-x","journal-title":"Angiogenesis"},{"key":"1066_CR9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/10807680151125555","volume":"17","author":"GC Chiou","year":"2001","unstructured":"Chiou GC (2001) Review: effects of nitric oxide on eye diseases and their treatment. J Ocul Pharmacol Ther 17:189\u2013198, doi: 10.1089\/10807680151125555","journal-title":"J Ocul Pharmacol Ther"},{"key":"1066_CR10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.arcmed.2007.05.003","volume":"38","author":"T He","year":"2007","unstructured":"He T, Xing YQ, Zhao XH, Ai M (2007) Interaction between iNOS and COX-2 in hypoxia-induced retinal neovascularization in mice. Arch Med Res 38:807\u2013815, doi: 10.1016\/j.arcmed.2007.05.003","journal-title":"Arch Med Res"},{"key":"1066_CR11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000110027","volume":"74","author":"T He","year":"2007","unstructured":"He T, Ai M, Zhao XH, Xing YQ (2007) Inducible nitric oxide synthase mediates hypoxia-induced hypoxia-inducible factor-1 alpha activation and vascular endothelial growth factor expression in oxygen-induced retinopathy. Pathobiology 74:336\u2013343, doi: 10.1159\/000110027","journal-title":"Pathobiology"},{"key":"1066_CR12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/jnci\/90.8.587","volume":"90","author":"O Gallo","year":"1998","unstructured":"Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, Ziche M (1998) Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90:587\u2013596, doi: 10.1093\/jnci\/90.8.587","journal-title":"J Natl Cancer Inst"},{"key":"1066_CR13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2337\/diab.41.4.552","volume":"41","author":"JA Corbett","year":"1992","unstructured":"Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, McDaniel ML (1992) Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552\u2013556, doi: 10.2337\/diabetes.41.4.552","journal-title":"Diabetes"},{"key":"1066_CR14","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1021\/bi972065t","volume":"37","author":"R Bryk","year":"1998","unstructured":"Bryk R, Wolff DJ (1998) Mechanism of inducible nitric oxide synthase inactivation by aminoguanidine and L-N6-(1-iminoethyl)lysine. Biochemistry 37:4844\u20134852, doi: 10.1021\/bi972065t","journal-title":"Biochemistry"},{"key":"1066_CR15","first-page":"101","volume":"35","author":"LE Smith","year":"1994","unstructured":"Smith LE, Wesolowski E, McLellan A, Kostyk SK, D\u2019Amato R, Sullivan R, D\u2019Amore PA (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101\u2013111","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1066_CR16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s001250051685","volume":"44","author":"D Zhang","year":"2001","unstructured":"Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX (2001) Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 44:757\u2013765, doi: 10.1007\/s001250051685","journal-title":"Diabetologia"},{"key":"1066_CR17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1096\/fj.01-0651fje","volume":"16","author":"R Benelli","year":"2002","unstructured":"Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, Cassatella M, Noonan DM, Albini A (2002) Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 16:267\u2013269","journal-title":"FASEB J"},{"key":"1066_CR18","doi-asserted-by":"crossref","first-page":"9492","DOI":"10.1074\/jbc.M108004200","volume":"277","author":"G Gao","year":"2002","unstructured":"Gao G, Li Y, Gee S, Dudley A, Fant J, Crosson C, Ma JX (2002) Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 277:9492\u20139497, doi: 10.1074\/jbc.M108004200","journal-title":"J Biol Chem"},{"key":"1066_CR19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/1573399054022839","volume":"1","author":"JX Ma","year":"2005","unstructured":"Ma JX, Zhang SX, Wang JJ (2005) Down-regulation of angiogenic inhibitors: a potential pathogenic mechanism for diabetic complications. Curr Diabetes Rev 1:183\u2013196, doi: 10.2174\/1573399054022839","journal-title":"Curr Diabetes Rev"},{"key":"1066_CR20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1359-6446(01)02160-2","volume":"7","author":"G Gao","year":"2002","unstructured":"Gao G, Ma J (2002) Tipping the balance for angiogenic disorders. Drug Discov Today 7:171\u2013172, doi: 10.1016\/S1359-6446(01)02160-2","journal-title":"Drug Discov Today"},{"key":"1066_CR21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.yapd.2006.04.010","volume":"53","author":"A Drack","year":"2006","unstructured":"Drack A (2006) Retinopathy of prematurity. Adv Pediatr 53:211\u2013226, doi: 10.1016\/j.yapd.2006.04.010","journal-title":"Adv Pediatr"},{"key":"1066_CR22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.eye.6701476","volume":"18","author":"R Williams","year":"2004","unstructured":"Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A (2004) Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 18:963\u2013983, doi: 10.1038\/sj.eye.6701476","journal-title":"Eye"},{"key":"1066_CR23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.7.1019","volume":"122","author":"DS Friedman","year":"2004","unstructured":"Friedman DS, O\u2019Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:564\u2013572, doi: 10.1001\/archopht.122.7.1019","journal-title":"Arch Ophthalmol"},{"key":"1066_CR24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bjo.86.7.716","volume":"86","author":"I Kocur","year":"2002","unstructured":"Kocur I, Resnikoff S (2002) Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 86:716\u2013722, doi: 10.1136\/bjo.86.7.716","journal-title":"Br J Ophthalmol"},{"key":"1066_CR25","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1517\/13543784.16.8.1209","volume":"16","author":"C Hernandez","year":"2007","unstructured":"Hernandez C, Simo R (2007) Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. Expert Opin Investig Drugs 16:1209\u20131226, doi: 10.1517\/13543784.16.8.1209","journal-title":"Expert Opin Investig Drugs"},{"key":"1066_CR26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275\u2013278, doi: 10.1097\/00006982-200603000-00004","journal-title":"Retina"},{"key":"1066_CR27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ajo.2006.02.015","volume":"142","author":"Y Oshima","year":"2006","unstructured":"Oshima Y, Sakaguchi H, Gomi F, Tano Y (2006) Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142:155\u2013158, doi: 10.1016\/j.ajo.2006.02.015","journal-title":"Am J Ophthalmol"},{"key":"1066_CR28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1444-0938.2008.00305.x","volume":"91","author":"P Wijngaarden van","year":"2008","unstructured":"van Wijngaarden P, Qureshi SH (2008) Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. Clin Exp Optom 91:427\u2013437, doi: 10.1111\/j.1444-0938.2008.00305.x","journal-title":"Clin Exp Optom"},{"issue":"6","key":"1066_CR29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/eye.2008.86","volume":"22","author":"H Dadgostar","year":"2008","unstructured":"Dadgostar H, Waheed N (2008) The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye 22(6):761\u2013767","journal-title":"Eye"},{"key":"1066_CR30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ajo.2007.09.031","volume":"145","author":"ZF Bashshur","year":"2008","unstructured":"Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145:249\u2013256, doi: 10.1016\/j.ajo.2007.09.031","journal-title":"Am J Ophthalmol"},{"key":"1066_CR31","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1167\/iovs.05-0518","volume":"47","author":"C Kaur","year":"2006","unstructured":"Kaur C, Sivakumar V, Foulds WS (2006) Early response of neurons and glial cells to hypoxia in the retina. Invest Ophthalmol Vis Sci 47:1126\u20131141, doi: 10.1167\/iovs.05-0518","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1066_CR32","first-page":"335","volume":"19","author":"N Shams","year":"2006","unstructured":"Shams N, Ianchulev T (2006) Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 19:335\u2013344","journal-title":"Ophthalmol Clin North Am"},{"key":"1066_CR33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000059634","volume":"216","author":"LO Hattenbach","year":"2002","unstructured":"Hattenbach LO, Falk B, Nurnberger F, Koch FH, Ohrloff C (2002) Detection of inducible nitric oxide synthase and vascular endothelial growth factor in choroidal neovascular membranes. Ophthalmologica 216:209\u2013214, doi: 10.1159\/000059634","journal-title":"Ophthalmologica"},{"key":"1066_CR34","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1172\/JCI10874","volume":"107","author":"F Sennlaub","year":"2001","unstructured":"Sennlaub F, Courtois Y, Goureau O (2001) Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest 107:717\u2013725, doi: 10.1172\/JCI10874","journal-title":"J Clin Invest"},{"key":"1066_CR35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bjp.0702986","volume":"129","author":"E Pipili-Synetos","year":"2000","unstructured":"Pipili-Synetos E, Kritikou S, Papadimitriou E, Athanassiadou A, Flordellis C, Maragoudakis ME (2000) Nitric oxide synthase expression, enzyme activity and NO production during angiogenesis in the chick chorioallantoic membrane. Br J Pharmacol 129:207\u2013213, doi: 10.1038\/sj.bjp.0702986","journal-title":"Br J Pharmacol"},{"key":"1066_CR36","first-page":"1033","volume":"40","author":"N Ghiso","year":"1999","unstructured":"Ghiso N, Rohan RM, Amano S, Garland R, Adamis AP (1999) Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. Invest Ophthalmol Vis Sci 40:1033\u20131039","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1066_CR37","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.lfs.2007.09.014","volume":"81","author":"A Pyriochou","year":"2007","unstructured":"Pyriochou A, Vassilakopoulos T, Zhou Z, Papapetropoulos A (2007) cGMP-dependent and -independent angiogenesis-related properties of nitric oxide. Life Sci 81:1549\u20131554, doi: 10.1016\/j.lfs.2007.09.014","journal-title":"Life Sci"},{"key":"1066_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1381612043453531","volume":"10","author":"SA Mousa","year":"2004","unstructured":"Mousa SA, Mousa AS (2004) Angiogenesis inhibitors: current & future directions. Curr Pharm Des 10:1\u20139, doi: 10.2174\/1381612043453531","journal-title":"Curr Pharm Des"},{"key":"1066_CR39","doi-asserted-by":"crossref","first-page":"43836","DOI":"10.1074\/jbc.M106534200","volume":"276","author":"C Treins","year":"2001","unstructured":"Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E (2001) Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 276:43836\u201343841, doi: 10.1074\/jbc.M106534200","journal-title":"J Biol Chem"},{"key":"1066_CR40","first-page":"2282","volume":"14","author":"H Yan","year":"2008","unstructured":"Yan H, Guo Y, Zhang J, Ding Z, Ha W, Harding JJ (2008) Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats. Mol Vis 14:2282\u20132291","journal-title":"Mol Vis"},{"key":"1066_CR41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.abb.2003.08.013","volume":"419","author":"PJ Thornalley","year":"2003","unstructured":"Thornalley PJ (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419:31\u201340, doi: 10.1016\/j.abb.2003.08.013","journal-title":"Arch Biochem Biophys"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1066-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-009-1066-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-009-1066-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:40:46Z","timestamp":1559072446000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-009-1066-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,20]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1007\/s00417-009-1066-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,20]]}}}